Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Home-Based Corrective Exercise With Remote Reinforcement for Upper Crossed Syndrome

4 de noviembre de 2026 actualizado por: JORGE MONTERO CÁMARA, Cardenal Herrera University

Effects of a Home-Based Corrective Exercise Program With Active Remote Reinforcement on Craniovertebral Angle, Rounded Shoulder Posture, Thoracic Kyphosis, Pain, Cervical and Shoulder Disability, and Pulmonary Function i Adults With Upper Crossed Syndrome: A Two-Arm Parallel Randomized Controlled Trial

Upper Crossed Syndrome (UCS) is a musculoskeletal condition defined by simultaneous forward head posture (craniovertebral angle, CVA < 52°), rounded shoulders (RSP > 52°), and thoracic hyperkyphosis (> 42°). It is highly prevalent in sedentary workers and musicians and is associated with neck pain, shoulder pain, and reduced pulmonary function. This two-arm parallel randomized controlled trial will compare two home-based corrective exercise programs over 12 weeks in adults with confirmed UCS. Both groups (Experimental, EG; Control, CG) perform the same 20-minute program three times per week: diaphragmatic breathing re-education and targeted muscle strengthening and stretching. The EG additionally uses a volumetric incentive spirometer (Coach2, 4000 mL) as respiratory biofeedback and receives active remote reinforcement (biweekly video calls + asynchronous educational material from a physiotherapist); the CG performs the same exercises without the spirometer and receives only minimal adherence monitoring. Outcomes are assessed at baseline (week 0) and at weeks 4, 8, and 12. Primary outcome: craniovertebral angle (CVA) measured by lateral photogrammetry. Secondary outcomes: rounded shoulder angle (RSP), thoracic kyphosis (bubble inclinometer and smartphone inclinometer), pain (Visual Analogue Scale), cervical disability (Neck Disability Index), shoulder pain and disability (SPADI), exercise adherence, and pulmonary function (spirometry: FVC, FEV₁/FVC, MVV) at weeks 0 and 12. Recruitment will take place at the Associació Amics de la Música de Meliana, Fisioterapia A Punto, and Universidad Cardenal Herrera CEU (Valencia, Spain). A total of 96 participants (48 per arm) will be enrolled over a 2-year recruitment window.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

96

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Jorge M Montero-Cámara, PhD
  • Número de teléfono: +34611661505
  • Correo electrónico: jorge.camara@uchceu.es

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • • Confirmed UCS diagnosis, defined by the simultaneous presence of: (a) craniovertebral angle (CVA) < 52°; (b) rounded shoulder posture angle (RSP) > 52°; and (c) thoracic kyphosis angle > 42°.

    • Age between 18 and 65 years.
    • Available and willing to perform the home exercise program and to attend all four face-to-face assessment sessions (weeks 0, 4, 8, and 12).
    • Access to a camera-equipped device (smartphone or tablet) for remote monitoring and reinforcement.
    • Ability to understand the study procedures and to sign informed consent.

Exclusion Criteria:

  • Severe cervical or thoracic pathology: vertebral fracture, neoplasm, infection, or active systemic inflammatory disease.

    • Spinal surgery within the preceding 12 months.
    • Respiratory pathology contraindicating use of a volumetric incentive spirometer: recent pneumothorax (< 6 weeks), COPD GOLD grade III-IV, or unstable bronchial asthma.
    • Active physiotherapy treatment specifically targeting UCS within the preceding 3 months.
    • Pregnancy or breastfeeding.
    • Cognitive impairment or language barrier preventing comprehension of the exercise program.
    • Simultaneous participation in another clinical trial.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Experimental Group (EC)

Home-based corrective exercise program (3 sessions/week × 12 weeks, 20 min/session) combining: (1) diaphragmatic breathing re-education with a volumetric incentive spirometer (Coach2, 4000 mL, Smiths Medical) as biofeedback - 4 progressive levels, 10 repetitions; (2) muscle strengthening and stretching targeting the deep cervical flexors, lower and middle trapezius, rhomboids, and pectoral/suboccipital muscles. The EG additionally receives active remote reinforcement: a biweekly video call with a physiotherapist and asynchronous educational material (written guides and video tutorials) delivered via a messaging platform.

Home-based corrective exercise program (3 sessions/week × 12 weeks, 20 min/session) combining: (1) diaphragmatic breathing re-education with a volumetric incentive spirometer (Coach2, 4000 mL, Smiths Medical) as biofeedback - 4 progressive levels, 10 repetitions; (2) muscle strengthening and stretching targeting the deep cervical flexors, lower and middle trapezius, rhomboids, and pectoral/suboccipital muscles. The EG additionally receives active remote reinforcement: a biweekly video call with a physiotherapist and asynchronous educational material (written guides and video tutorials) delivered via a messaging platform.

Comparador activo: Control Group (CG)

Identical home-based corrective exercise program (3 sessions/week × 12 weeks, 20 min/session) with the same muscle strengthening and stretching exercises. The CG does not use an incentive spirometer (diaphragmatic breathing performed without device) and does not receive active remote reinforcement; adherence monitoring is minimal (standardized paper diary).

Identical home-based corrective exercise program (3 sessions/week × 12 weeks, 20 min/session) with the same muscle strengthening and stretching exercises. The CG does not use an incentive spirometer (diaphragmatic breathing performed without device) and does not receive active remote reinforcement; adherence monitoring is minimal (standardized paper diary).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Craniovertebral Angle (CVA)
Periodo de tiempo: Baseline (Week 0), Week 4, Week 8, Week 12

Angle formed between the horizontal line at the C7 spinous process and the line connecting C7 to the ipsilateral ear tragus, measured by lateral photogrammetry using standardized adhesive markers and Kinovea software. A lower CVA indicates greater forward head posture (normal > 52°).

Baseline (Week 0), Week 4, Week 8, Week 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Rounded Shoulder Posture Angle (RSP)
Periodo de tiempo: Baseline (Week 0), Week 4, Week 8, Week 12

Angle between the line connecting the C7 spinous process to the right acromion and the horizontal, measured by lateral photogrammetry (Kinovea). Values > 52° indicate rounded shoulder posture.

Baseline (Week 0), Week 4, Week 8, Week 12
Thoracic Kyphosis Angle - Bubble Inclinometer
Periodo de tiempo: Baseline (Week 0), Week 4, Week 8, Week 12

Single-inclinometer sequential method: the instrument (Baseline, Fabrication Enterprises Inc., White Plains, NY) is zeroed at T1 and the angle is read at T12. Three measurements per time point; mean used for analysis.

Baseline (Week 0), Week 4, Week 8, Week 12
Thoracic Kyphosis Angle - Smartphone Inclinometer
Periodo de tiempo: Baseline (Week 0), Week 4, Week 8, Week 12

Same T1-T12 sequential method using the Clinometer app (Plaincode) on iPhone 17. The upper corner of the narrow side of the phone is placed at T1 (zeroed to 0°), then moved to T12 (angle read). Three measurements per time point; mean used for analysis.

Baseline (Week 0), Week 4, Week 8, Week 12
Pain Intensity - Visual Analogue Scale (VAS)
Periodo de tiempo: Baseline (Week 0), Week 4, Week 8, Week 12

100-mm horizontal VAS (0 = no pain; 100 = worst imaginable pain) for neck and interscapular pain during the past week. Minimum clinically important difference (MCID): 15 mm.

Baseline (Week 0), Week 4, Week 8, Week 12
Cervical Disability - Neck Disability Index (NDI)
Periodo de tiempo: Baseline (Week 0), Week 4, Week 8, Week 12

10-item self-reported questionnaire assessing the impact of neck pain on daily activities; total score 0-50. Spanish validated version used. MCID: 5 points (10%). Interpretation: 0-8% no disability; 10-28% mild; 30-48% moderate; 50-64% severe; ≥ 64% complete disability.

Baseline (Week 0), Week 4, Week 8, Week 12
Shoulder Pain and Disability - SPADI
Periodo de tiempo: Baseline (Week 0), Week 4, Week 8, Week 12

13-item self-reported questionnaire with two subscales (Pain: 5 items; Disability: 8 items), each item scored 0-10. Total score 0-100 (higher = worse). MCID: 13-18 points. Spanish validated version used.

Baseline (Week 0), Week 4, Week 8, Week 12
Exercise Adherence
Periodo de tiempo: Weeks 1-12 (cumulative at each assessment point)

Percentage of prescribed sessions completed out of 36 planned sessions (3/week × 12 weeks), recorded in standardized session diaries. Adequate adherence defined as ≥ 70%

Weeks 1-12 (cumulative at each assessment point)
Forced Vital Capacity (FVC, % predicted)
Periodo de tiempo: Baseline (Week 0), Week 12

Spirometric measurement (forced vital capacity as percentage of age-sex-height-weight predicted value). ATS acceptability and reproducibility criteria applied; 3 measurements per session, mean used.

Baseline (Week 0), Week 12
FEV₁/FVC Ratio (% predicted)
Periodo de tiempo: Baseline (Week 0), Week 12

Ratio of forced expiratory volume in 1 second to forced vital capacity, expressed as percentage of predicted value.

Baseline (Week 0), Week 12
Maximum Voluntary Ventilation (MVV, % predicted)
Periodo de tiempo: Baseline (Week 0), Week 12

Spirometric measure of maximum airflow over 12-15 seconds, expressed as percentage of predicted value.

Baseline (Week 0), Week 12

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

9 de noviembre de 2026

Finalización primaria (Estimado)

9 de noviembre de 2028

Finalización del estudio (Estimado)

31 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

29 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Publicado por primera vez (Actual)

9 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir